Clinical Trial Update: Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

View source ↗

Summary

A clinical trial (SHIFT-IBD) is evaluating switching to the IL-23 inhibitor guselkumab in active inflammatory bowel disease patients who previously used ustekin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• Stelara (ustekinumab)
• TREMFYA (guselkumab)

Snippet

Sponsor: TIDHI Innovation Inc. | Conditions: Inflammatory Bowel Disease (IBD), Crohn Disease (CD) | Status: RECRUITING